Curatis Holding AG · SIX:CURN
Curatis — Kinarus — Investor Presentation (July 2023)
24 slides from Curatis's investor presentation, July 2023
Slide 1: Corporate deck
Corporate deck July 2023
Slide 2: Disclaimer
Disclaimer This Company Presentation and supporting material (together the “Material”) with regard to Kinarus AG (“Kinarus” or the “Company”) is based on information provided by the Company. It may only be used to the benefit of and the internal use of the receiver. Kinarus holds all rights related
Slide 3: Executive Summary
Executive Summary • Kinarus is a biotech company developing a combination therapy for Idiopathic Pulmonary Fibrosis, retinal, and autoimmune disorders • Key asset – KIN001 – p38 MAPK inhibitor pamapimod (Roche) + pioglitazone (marketed) • KIN001 unlocks the broad potential of p38 MAPK inhibition, a
Slide 4: Experienced Leadership
Experienced Leadership We are drug developers Dr. Alexander Bausch Chief Executive Officer Kinarus AG, www.kinarus.com Dr. Matthew Wright Claudia Berger Chief Operations Officer Chief Clinical Dev. Officer Head of Research Dr. Thierry Fumeaux Chief Medical Officer • Direct know-how and in-depth expe
Slide 5: Pamapimod
Pamapimod Clinical-stage p38 MAPK inhibitor in-licensed from Roche The Asset • p38 MAPK inhibitors were actively under development 2005-2010 for autoimmune indications (e.g. Rheumatoid Arthritis) • Pamapimod was discovered and developed by Roche ✓ Safe in preclinical and clinical testing ✓ Engages w
Slide 6: KIN001 for Idiopathic Pulmonary Fibrosis
KIN001 for Kinarus AG, www.kinarus.com Idiopathic Pulmonary Fibrosis Kinarus confidential – not for distibution
Slide 7: Idiopathic Pulmonary Fibrosis: More effective, better tolerated therapies needed
Idiopathic Pulmonary Fibrosis More effective, better tolerated therapies needed • IPF is a severe progressive fibrotic lung disease • Median survival two to five years, similar to many types of cancer • Limited therapeutic options • Esbriet® (pirfenidone; Roche) and Ofev® (nintedanib; BI) Kinarus AG
Slide 8: Idiopathic Pulmonary Fibrosis: A favorable market opportunity
Idiopathic Pulmonary Fibrosis A favorable market opportunity for a differentiated new drug • The incidence and prevalence of IPF is in the range of 0.09–1.30 and 0.33–4.51 per 10,000 persons(1) • Global market to reach USD 3.2B by 2025 Kinarus AG, www.kinarus.com • IPF qualifies for Orphan drug desi
Slide 9: KIN001: A potential differentiated treatment for IPF
Idiopathic Pulmonary Fibrosis KIN001: A potential differentiated treatment for IPF • KIN001 is a safe fixed dose combination • Favourable clinical data package for pamapimod (large phase 1 program, two phase 2 trials (Roche) • Pamapimod - complete tox package for regulatory submission in-hand (Roche
Slide 10: Targeting multiple mechanisms in IPF
KIN001 and Fibrosis Targeting multiple mechanisms in IPF Inflammation Epithelial-mesenchymal transition (EMT) IL-17 / TGFbeta Pioglitazone MKKs Pioglitazone Pioglitazone Pamapimod Pamapimod Pamapimod PPARg Kinarus AG, www.kinarus.com p38 MAPK MK2/3 TNF-α, IL-1β, IL-6, TGF-β, cytokines/chemokines Inh
Slide 11: Reduces Lung Fibrosis and Inflammation
KIN001 Reduces Lung Fibrosis and Inflammation Efficacious on top of Pirfenidone Reduced Lung Fibrosis Effect of KIN001 on Lung Fibrosis Score vs. Pioglitazone, Pamapimod, and Pirfenidone Ashcroft Score - 3 Weeks after Bleomycin 4.8 * 4.3 ** 3.7 3.7 3.5 3.4 3.1 Fibrotic Area Kinarus AG, www.kinarus.c
Slide 12: Broad Repression of Key Cytokines and Chemokines
Broad Repression of Key Cytokines and Chemokines mRNA expression analysis reveals synergistic anti-inflammatory action of KIN001 in lung Inflammatory signals RNASeq whole genome lung expression data from Mouse bleomycin study 2 KIN001 Interleukins and receptors adjusted significance (p) value Gene G
Slide 13: IPF Phase 2 Trial: Ready for Regulatory Submission
IPF Phase 2 Trial Ready for Regulatory Submission Placebo (n=25) plus published placebo data integrated into statistical model Screening Randomization Pamapimod 75 mg bid+ pioglitazone 15 mg bid (n=50) Kinarus AG, www.kinarus.com Treatment duration: 52 weeks WK -4 BL/D1 Primary endpoint: Mean absolu
Slide 14: Strategy for rapid clinical development
KIN001 in Idiopathic Pulmonary Fibrosis Strategy for rapid clinical development • Positive Phase 2 data will represent a substantial value creation • In order to rapidly launch Phase 3 we will • Conduct pre-IND (FDA) and scientific advice (EMA) discussions to define path to NDA • The comprehensive s
Slide 15: Strategic options after Phase 2
KIN001 in Idiopathic Pulmonary Fibrosis Strategic options after Phase 2 • Positive Phase 2 data will unlock attractive business/partnering options • Corporate acquisition after Phase 2 • Reduced Phase 3 risk with a clear path to NDA may increase the appetite for early trade sale Kinarus AG, www.kina
Slide 16: KIN001 for Wet Age-Related Macular Degeneration
KIN001 for Kinarus AG, www.kinarus.com Wet Age-Related Macular Degeneration Kinarus confidential – not for further distibution
Slide 17: KIN001 in Age-Related Macular Degeneration (wet AMD)
KIN001 in Age-Related Macular Degeneration (wet AMD) The leading cause of blindness in the elderly • No oral treatment for wet AMD exists today • Current treatments are all injected directly into the eye: • Eylea® and Lucentis® targeting VEGF are current mainstay therapies • Others are Vabysmo® (Roc
Slide 18: Unique positioning opportunity in wet AMD
KIN001 in Wet Macular degeneration (wet AMD) Unique positioning opportunity - complement, not replace Lucentis/Eylea • KIN001 is well suited to be an effective treatment for wet AMD • Pamapimod and Pioglitazone are implicated in mechanisms of AMD • Studies suggest that MAPKs are involved in oxidativ
Slide 19: KIN001 is Highly Effective in Preclinical Studies
KIN001 is Highly Effective in Preclinical Studies Reduces Choroidal Neovascularization and Retinal Fibrosis in Mouse and Primate Endothelial area (new vessels) Fibrosis area choroidal CNV area immunostained for isolectin (left); choroidal CNV area immunostained for collagen 1a Effect of KIN001 on Ch
Slide 20: KIN001: A strong candidate for early licensing
Wet Age-Related Macular Degeneration KIN001: A strong candidate for early licensing • With a ready-to-launch Phase 2 trial KIN001 is a compelling licensing opportunity • KIN001 is a strategic fit to diverse potential partners • Companies with a presence in wet AMD to complement existing franchise an
Slide 21: KIN001 - a Strong Platform of Opportunities
KIN001 - a Strong Platform of Opportunities Several additional indications can be explored and out-licensed • General Strategy in new Indications • Identify indications with role for p38, generate preclinical PoC, generate IP, out- license/partner • Kinarus has filed combination patents covering KIN
Slide 22: KIN001 - a Strong Platform of Opportunities (NASH, Psoriasis, RA)
KIN001 - a Strong Platform of Opportunities Several additional indications can be explored and out-licensed • 2. NASH – non-alcoholic steatohepatitis: • Strong preclinical evidence for p38 MAPK (pamapimod) and PPARg (pioglitazone) • Newly emerging preclinical models allow assessment of potential of
Slide 23: Strong Patent Estate
Strong Patent Estate Strong composition of matter protection through 2037 2017 2019 2016 2018 2022 2037 2040 ¥ Pamapimod Roche Patent - Licensed Ongoing data exclusivity *Combination Patent for PPAR Agonists and P38 MAPK inhibitors. Pharmaceutical compositions and use in Cancer **Combination Patent
Slide 24: Thank you
Thank you confidential - not for further distribution